Cargando…
Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer
PURPOSE: Cisplatin-associated arterial and venous thromboembolic events (TEEs) are becoming an increasing concern. In patients with small-cell lung cancer (SCLC) who are treated using cisplatin-based chemotherapy, we assume that the overall risk of TEEs is high. However, cisplatin-associated vascula...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Cancer Association
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4614217/ https://www.ncbi.nlm.nih.gov/pubmed/25672586 http://dx.doi.org/10.4143/crt.2014.045 |
_version_ | 1782396369908006912 |
---|---|
author | Lee, Yun-Gyoo Lee, Eunyoung Kim, Inho Lee, Keun-Wook Kim, Tae Min Lee, Se-Hoon Kim, Dong-Wan Heo, Dae Seog |
author_facet | Lee, Yun-Gyoo Lee, Eunyoung Kim, Inho Lee, Keun-Wook Kim, Tae Min Lee, Se-Hoon Kim, Dong-Wan Heo, Dae Seog |
author_sort | Lee, Yun-Gyoo |
collection | PubMed |
description | PURPOSE: Cisplatin-associated arterial and venous thromboembolic events (TEEs) are becoming an increasing concern. In patients with small-cell lung cancer (SCLC) who are treated using cisplatin-based chemotherapy, we assume that the overall risk of TEEs is high. However, cisplatin-associated vascular toxicity in patients with SCLC has been overlooked to date. The aim of this study was to determine the incidence of TEEs in patients with SCLC and to analyze the predictors for TEE occurrence. MATERIALS AND METHODS: We retrospectively analyzed 277 patients who received chemotherapy for SCLC between 2006 and 2012. As the influence of chemotherapy on TEE occurrence developed after its initiation, a time-dependent Cox regression analysis was used to estimate the significant predictors for TEE. RESULTS: Among the 277 patients, 30 patients (11%) developed a TEE. The 3-month, 6-month, and 1-year cumulative incidences of TEEs were 5.0%, 9.1%, and 10.2%, respectively. Of 30 total TEEs, 22 (73%) occurred between the time of initiation and 4 weeks after the last dose of platinum-based chemotherapy. Approximately 218 patients (79%) received cisplatin-based chemotherapy. In multivariate analysis, cisplatin-based chemotherapy was an independent risk factor for TEE occurrence (hazard ratio [HR], 4.36; p=0.05). Variables including smoking status (common HR, 2.14; p=0.01) and comorbidity index (common HR, 1.60; p=0.05) also showed significant association with TEE occurrence. CONCLUSION: The 1-year cumulative incidence of TEE is 10.2% in Asian patients with SCLC. Cisplatin-based chemotherapy in SCLC might be a strong predictor for the risk of TEE. |
format | Online Article Text |
id | pubmed-4614217 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Korean Cancer Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-46142172015-10-22 Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer Lee, Yun-Gyoo Lee, Eunyoung Kim, Inho Lee, Keun-Wook Kim, Tae Min Lee, Se-Hoon Kim, Dong-Wan Heo, Dae Seog Cancer Res Treat Original Article PURPOSE: Cisplatin-associated arterial and venous thromboembolic events (TEEs) are becoming an increasing concern. In patients with small-cell lung cancer (SCLC) who are treated using cisplatin-based chemotherapy, we assume that the overall risk of TEEs is high. However, cisplatin-associated vascular toxicity in patients with SCLC has been overlooked to date. The aim of this study was to determine the incidence of TEEs in patients with SCLC and to analyze the predictors for TEE occurrence. MATERIALS AND METHODS: We retrospectively analyzed 277 patients who received chemotherapy for SCLC between 2006 and 2012. As the influence of chemotherapy on TEE occurrence developed after its initiation, a time-dependent Cox regression analysis was used to estimate the significant predictors for TEE. RESULTS: Among the 277 patients, 30 patients (11%) developed a TEE. The 3-month, 6-month, and 1-year cumulative incidences of TEEs were 5.0%, 9.1%, and 10.2%, respectively. Of 30 total TEEs, 22 (73%) occurred between the time of initiation and 4 weeks after the last dose of platinum-based chemotherapy. Approximately 218 patients (79%) received cisplatin-based chemotherapy. In multivariate analysis, cisplatin-based chemotherapy was an independent risk factor for TEE occurrence (hazard ratio [HR], 4.36; p=0.05). Variables including smoking status (common HR, 2.14; p=0.01) and comorbidity index (common HR, 1.60; p=0.05) also showed significant association with TEE occurrence. CONCLUSION: The 1-year cumulative incidence of TEE is 10.2% in Asian patients with SCLC. Cisplatin-based chemotherapy in SCLC might be a strong predictor for the risk of TEE. Korean Cancer Association 2015-10 2015-01-02 /pmc/articles/PMC4614217/ /pubmed/25672586 http://dx.doi.org/10.4143/crt.2014.045 Text en Copyright © 2015 by the Korean Cancer Association This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Lee, Yun-Gyoo Lee, Eunyoung Kim, Inho Lee, Keun-Wook Kim, Tae Min Lee, Se-Hoon Kim, Dong-Wan Heo, Dae Seog Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer |
title | Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer |
title_full | Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer |
title_fullStr | Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer |
title_full_unstemmed | Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer |
title_short | Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer |
title_sort | cisplatin-based chemotherapy is a strong risk factor for thromboembolic events in small-cell lung cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4614217/ https://www.ncbi.nlm.nih.gov/pubmed/25672586 http://dx.doi.org/10.4143/crt.2014.045 |
work_keys_str_mv | AT leeyungyoo cisplatinbasedchemotherapyisastrongriskfactorforthromboemboliceventsinsmallcelllungcancer AT leeeunyoung cisplatinbasedchemotherapyisastrongriskfactorforthromboemboliceventsinsmallcelllungcancer AT kiminho cisplatinbasedchemotherapyisastrongriskfactorforthromboemboliceventsinsmallcelllungcancer AT leekeunwook cisplatinbasedchemotherapyisastrongriskfactorforthromboemboliceventsinsmallcelllungcancer AT kimtaemin cisplatinbasedchemotherapyisastrongriskfactorforthromboemboliceventsinsmallcelllungcancer AT leesehoon cisplatinbasedchemotherapyisastrongriskfactorforthromboemboliceventsinsmallcelllungcancer AT kimdongwan cisplatinbasedchemotherapyisastrongriskfactorforthromboemboliceventsinsmallcelllungcancer AT heodaeseog cisplatinbasedchemotherapyisastrongriskfactorforthromboemboliceventsinsmallcelllungcancer |